Francesco de Rubertis, a co-founder of Medicixi Ventures, has unveiled the next generation of the venture-backed asset-centric biopharma model with the creation of Centessa Pharmaceuticals Ltd. The new company was created by acquiring, in all-share transactions, total control of 10 companies from the Medicxi portfolio. Read more at BioWorld.com
2021: Priorities for European Pharma & What does the investment landscape look like post Covid-19?
This year, in collaboration with Dechert, we held a virtual version of our leading Annual Healthcare Investor Conference on the 8th of October. The 12th event discussed how life sciences innovation is driving change – from the myriad international efforts against Covid-19 to how we communicate with the investment community. The virtue of virtual was […]
– Future of healthcare conference in partnership with Dechert LLP goes virtual – Panellists include eminent leaders from healthcare industry and investment community LONDON, Oct. 5, 2020 /PRNewswire/ — Optimum Strategic Communications (Optimum), the international strategic healthcare communications firm, will be hosting its 12th Annual Healthcare Investor Conference virtually, in partnership with Dechert LLP, on Thursday, 8 October 2020. In an unprecedented time for […]
Phase 2 data from Arix portfolio company Amplyx and why anti-infectives are especially important now during the pandemic.
